Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Real-life data of Nivolumab in...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Real-life data of Nivolumab in second-line metastatic renal cell cancer

Real-life data of Nivolumab in second-line metastatic renal cell cancer

Bibliographic Details
Main Authors: L.F. Sánchez-Cousido, Á. Rodríguez Sánchez, A. Lanz Lozano, M. López Flores, A. López-González, C. Castañón González, B. Nieto Mangudo, P. Diz Taín, Á. García-Palomo
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S266616832036242X
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S266616832036242X

Similar Items

  • Real-life data of Atezolizumab in urothelial carcinoma, second-line metastatic disease
    by: L.F. Sánchez-Cousido, et al.
    Published: (2020-11-01)
  • Real-life data of Cabazitaxel-Prednisone second-line scheme in metastatic castration-resistant prostate cancer
    by: L.F. Sánchez-Cousido, et al.
    Published: (2020-11-01)
  • Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
    by: Jun Teishima, et al.
    Published: (2023-03-01)
  • First-line treatment of metastatic melanoma: role of nivolumab
    by: Force J, et al.
    Published: (2017-02-01)
  • A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
    by: Dahlia Fedele, et al.
    Published: (2024-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs